Jiefeng Luo

Mr. Jiefeng Luo

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2026 in Cancer
Verified
Journal Article
Open access
JLJiefeng Luo
Jiefeng Luo
ZLZhengxiong Li
Zhengxiong Li
JGJun Ge
Jun Ge
SCSizhen Cai
Sizhen Cai
XMXinyi Mo
Xinyi Mo
JLJiyong Liu
Jiyong Liu
Background: Nivolumab plus ipilimumab has shown survival benefits as first‐line treatment for unresectable hepatocellular carcinoma (HCC) but their high cost raises concerns about value. This study assessed the cost‐effectiveness of nivolumab plus ipilimumab compared with lenvatinib or sorafenib from a United States (US) health care payer perspective. Methods: A partitioned survival model was developed using data from the CheckMate 9DW trial with a 10‐year horizon. Costs and outcomes were discounted by 3% annually. Clinical inputs were derived from CheckMate 9DW trial, and cost inputs were obtained from public databases and published studies. Primary outcomes were quality‐adjusted life years (QALYs), total costs, life years (LYs), and incremental cost‐effectiveness ratios (ICERs). Sensitivity and scenario analyses were conducted to test uncertainties. Results: Nivolumab plus ipilimumab produced an incremental gain of 0.66 QALYs at an additional cost of $132,652, yielding an ICER of $200,409/QALY, above US willingness‐to‐pay thresholds ($100,000/QALY and $150,000/QALY). Probabilistic sensitivity analysis indicated a low probability of cost‐effectiveness at current prices (4.6%–20%). Scenario analyses showed that extending maintenance nivolumab dosing from every 4 weeks to every 8 weeks reduced the ICER to $82,202/QALY, making the regimen cost‐effective. Moderate price reductions also substantially increased the likelihood of cost‐effectiveness. Conclusions: Nivolumab plus ipilimumab is unlikely to be cost‐effective as first‐line therapy for unresectable HCC from US health care payer perspective. However, extended dosing interval or price reductions may render the regimen economically viable, with important implications for clinical practice, payers, and policy.

27 April 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
JLJiefeng Luo
Jiefeng Luo
MYMengting Yang
Mengting Yang
LZLinan Zeng
Linan Zeng
XPXiangcheng Pan
Xiangcheng Pan
DLDan Liu
Dan Liu
LZlingli zhang
lingli zhang
Purpose. To systematically evaluate the safety and effectiveness of different dosages of recombinant human interferon α1b (IFNα1b) inhaled for bronchiolitis in children. Methods. 7 databases, including PubMed, EMBASE, Cochrane Library, Web of Science, CNKI, Wanfang Database, and VIP, were searched. The search time was from their inception dates to March 28, 2022. A randomized controlled trial (RCT) of 2 μg/kg IFNα1b (low dosage group) monotherapy or in combination with other drugs vs. 4 μg/kg IFNα1b (high dosage group) monotherapy or in combination with the other drugs was included. The risk of bias 2.0 evaluated the RCT’s quality, and the grading of recommendations assessment, development and evaluation (GRADE) tool was used for evaluating the overall quality of the evidence. Then, a meta-analysis was performed by RevMan 5.4. Results. A total of 13 RCTs with 1719 children were included. The meta-analysis results showed that the high dosage group was significantly shorter than the low dosage group of the duration of hospital stays (MD = −0.40, 95%CI (−0.73, −0.07), = 0.02) (low quality), three depressions sign disappearing time (MD = −0.60, 95%CI (−1.05, −0.14), = 0.010) (low quality), and wheeze disappearing time (MD = −0.62, 95%CI (−1.17, −0.06), = 0.03) (low quality). There was no significant difference between the two groups in coughing disappearing time, pulmonary rales disappearing time, wheezing sound disappearing time, or adverse event rates. Conclusions. Compared with low dosage IFNα1b, high dosage IFNα1b reduces the duration of hospital stays, the disappearance time of the three depression signs, and the disappearance time of wheeze in the treatment of bronchiolitis in children. Limited by the low quality of the evidence, the conclusions still need to be supported by high-quality studies.

12 November 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
JLJiefeng Luo
Jiefeng Luo
DLDan Liu
Dan Liu
JLJiyong Liu
Jiyong Liu
Introduction Premature birth is the leading cause of neonatal mortality. Cervical length shortening during pregnancy serves as the gold standard for predicting preterm birth. Although several interventions have been applied to reduce the incidence of preterm birth in short cervix pregnant women, the optimal intervention in clinical practice remains controversial. The aim of this study is to conduct a network meta-analysis to explore the optimal intervention for preventing preterm birth among pregnant women with a short cervix. Methods and analysis We will search electronic information databases including PubMed, Embase Ovid, Cochrane Library Ovid, Wanfang Data, China Science and Technology Journal Database(VIP) and clinical trial registry websites (US Clinical Trials Registry and China Clinical Trials Registry) until 1 January 2024. Randomised controlled trials (RCTs) comparing two or more interventions to prevent preterm birth in short cervix pregnant women will be included. The primary outcomes are preterm birth rate at <37 weeks and the composite neonatal adverse outcome, secondary outcomes include spontaneous preterm birth rate at <37 weeks, preterm birth rate at <34 weeks, spontaneous preterm birth rate at <34 weeks, week of gestation, birth weight of the newborn, perinatal mortality and neonatal admission rate. Risk of bias 2.0 (ROB 2.0) will be used to assess the risk of bias in the RCT, and the Confidence in Network Meta-Analysis software will be used to assess the certainty of the generated evidence. The network meta-analysis will be conducted using the gemtc package in R 4.2.2. Two investigators independently performed article screening, data extraction and quality assessment. In addition, subgroup analyses and sensitivity analyses will be used to assess the robustness of the findings. Ethics and dissemination Ethical considerations will not be required. Results will be published in a peer-review journal. PROSPERO registration number CRD42022315200.